Pronostic des métastases ganglionnaires dans le mHSPC : faut-il intensifier de la même manière ?

D’après : Differential treatment response with nodal metastases in metastatic hormone-sensitive prostate cancer (mHSPC) and evaluation of nodal (N) burden as a prognostic biomarker -ancillary studies of the docetaxel and abiraterone acetate and prednisolone (AAP) phase III trials from STAMPEDE (Áine M. Haran (Bath, United Kingdom))